Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment

BMC Infectious Diseases

Momar Ndao⁵  Francois Chappuis¹  Qianqian Miao⁵  Marylise Holst⁴  Anne Mauris³  Eric Chatelain²  Yves Jackson⁴ 

[1]Division of international and humanitarian medicine, Department of community medicine, primary care and emergency medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland

[2]Drug for Neglected Diseases Initiative, Geneva, Switzerland

[3]Department of genetics and laboratory analysis, Geneva University Hospitals and University of Geneva, Geneva, Switzerland

[4]Division of primary care medicine, Department of community medicine, primary care and emergency medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland

[5]National Reference Center for Parasitology, Department of Medicine, Division of Infectious Diseases, Research Institute of the McGill University Health Centre, Montreal General Hospital, Montreal, Canada

关键词: Rapid diagnostic tests;    PCR;    Serology;    Follow-up;    Diagnostic tests;    Trypanosoma cruzi;    Chagas disease;   

Others  :  1158392
DOI  :  10.1186/1471-2334-13-85

 received in 2012-09-13, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

With declining vectorial transmission, Chagas disease predominantly affects adults nowadays. The efficacy of nifurtimox in the chronic phase in adult patients is poorly known, particularly in regions where there is no risk of reinfection. Recommendations for treatment outcome assessment rely on serological follow-up. We evaluated the serological and parasitological response to nifurtimox in a cohort of adult patients three years post-treatment in Switzerland.

Methods

Patients treated with nifurtimox in 2008 during a cross-sectional study in Geneva, Switzerland, were contacted for follow-up in 2011. Two ELISAs and a rapid immunochromatographic test were used to test 2008 and 2011 serum samples simultaneously. In addition, conventional and real-time PCR were performed on 2011 samples.

Results

Thirty-seven (84.1%) of 44 eligible patients, predominantly female, middle-aged, Bolivians at the indeterminate stage, were enrolled. All 2011 ELISA and immunochromatographic tests were positive. Twenty-eight (75.7%) patients presented a lower optical density (OD) in 2011 compared to 2008. This OD difference was significant in both commercial (P < 0.001) and in-house (P = 0.002) ELISAs. Agreement between the two ELISAs was low (Kappa = 0.469). All patients had negative conventional PCR results but one (2.7%) was positive with real-time PCR.

Conclusion

Our results highlight the inadequacy of serology for assessing response in adults, three years after treatment. In our cohort, 97.3% had results that could either indicate treatment failure or persistant humoral response despite treatment. The lack of accurate early post-treatment tests of cure prevents appropriate patients information and councelling. New follow-up tests are needed to assess treatments efficacy given the large adult population in need of antiparasitic therapy.

【 授权许可】

   
2013 Jackson et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bern C, Montgomery SP: An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009, 49(5):e52-e54.
• [2]World Health Organization: Control and prevention of Chagas disease in Europe. Report of a WHO Informal Consultation (jointly organized by WHO headquarters and the WHO Regional Office for Europe) Geneva, Switzerland, 17–18 December 2009. Geneva: WHO; 2009.
• [3]World Health Organization: Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Geneva: WHO; 2010.
• [4]Coura JR, Borges-Pereira J: Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 2011, 106(6):641-645.
• [5]Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, et al.: Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007, 298(18):2171-2181.
• [6]Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F: Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010, 51(10):e69-e75.
• [7]Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R: Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009, 64(6):1139-1147.
• [8]World Health Organization: Control of Chagas disease. In World Health Organ Tech Rep Ser, vol. 905, 2002/07/03. Brasilia (Brazil): WHO; 2002. i-vi, 1–109, back cover
• [9]Viotti R, Vigliano C, Alvarez MG, Lococo B, Petti M, Bertocchi G, Armenti A, De Rissio AM, Cooley G, Tarleton R, et al.: Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 2011, 5(9):e1314.
• [10]Rassi A Jr, Rassi A, Marin-Neto JA: Chagas disease. Lancet 2010, 375(9723):1388-1402.
• [11]Chappuis F, Mauris A, Holst M, Albajar-Vinas P, Jannin J, Luquetti AO, Jackson Y: Validation of a rapid immunochromatographic assay for diagnosis of Trypanosoma cruzi infection among Latin-American Migrants in Geneva, Switzerland. J Clin Microbiol 2010, 48(8):2948-2952.
• [12]Otani MM, Vinelli E, Kirchhoff LV, del Pozo A, Sands A, Vercauteren G, Sabino EC: WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 2009, 49(6):1076-1082.
• [13]Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, Cura C, Auter F, Veron V, Qvarnstrom Y, et al.: International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011, 5(1):e931.
• [14]Jackson Y, Getaz L, Wolff H, Holst M, Mauris A, Tardin A, Sztajzel J, Besse V, Loutan L, Gaspoz JM, et al.: Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 2010, 4(2):e592.
• [15]Berrizbietia M, Ndao M, Gottschalk M, Ache A, Vasquez F, Lacouture S, Medina M, Ward BJ: Development and comparison of enzyme immunoassays for diagnosis of Chagas’ disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays. J Clin Microbiol 2004, 42(4):1766-1769.
• [16]Ndao M, Kelly N, Normandin D, Maclean JD, Whiteman A, Kokoskin E, Arevalo I, Ward BJ: Trypanosoma cruzi infection of squirrel monkeys: comparison of blood smear examination, commercial enzyme-linked immunosorbent assay, and polymerase chain reaction analysis as screening tests for evaluation of monkey-related injuries. Comp Med 2000, 50(6):658-665.
• [17]Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA: Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007, 40(1):1-10.
• [18]Coura JR, de Abreu LL, Willcox HP, Petana W: Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas’ disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 1997, 30(2):139-144.
• [19]Cancado JR: Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002, 44(1):29-37.
• [20]Viotti R, Vigliano C, Armenti H, Segura E: Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994, 127(1):151-162.
• [21]Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A: Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144(10):724-734.
• [22]Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, Sosa-Estani S, Yusuf S: The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009, 104(Suppl 1):319-324.
• [23]Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU: ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis 2010, 10:337. BioMed Central Full Text
• [24]Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, Favaloro RR, Freilij H, Schijman AG: Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 2009, 3(4):e419.
• [25]Schmunis GA, Yadon ZE: Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2009, 115(1–2):14-21.
• [26]Jackson Y, Castillo S, Hammond P, Besson M, Brawand-Bron A, Urzola D, Gaspoz JM, Chappuis F: Metabolic, mental health, behavioural and socioeconomic characteristics of migrants with Chagas disease in a non-endemic country. Trop Med Int Health 2012, 17(5):595-603.
• [27]Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, et al.: Identification of novel diagnostic serum biomarkers for Chagas’ disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010, 48(4):1139-1149.
• [28]Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Armenti A, et al.: Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009, 49(11):1675-1684.
• [29]Vitelli-Avelar DM, Sathler-Avelar R, Wendling AP, Rocha RD, Teixeira-Carvalho A, Martins NE, Dias JC, Rassi A, Luquetti AO, Eloi-Santos SM, et al.: Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory. J Immunol Methods 2007, 318(1–2):102-112.
• [30]Fernández-Villegas A, Pinazo MJ, Marañón C, Thomas MC, Posada E, Carrilero B, Segovia M, Gascon J, López MC: Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers. BMC Infect Dis 2011, 11:206. BioMed Central Full Text